Abstract
Background
A decreased radioiodine uptake is associated with high recurrence rate and reduced survival in papillary thyroid carcinoma (PTC). Sodium iodide symporter (NIS) expression status in aggressive PTC variants is unknown.
Methods
NIS expression in conventional PTC and aggressive PTC variants such as tall cell variant (TCV) and diffuse sclerosing variant (DSPTC) was investigated using immunohistochemical detection.
Results
Patients having TCV and DSPTC were significantly more likely to have extrathyroidal extension and lymph nodes metastases (P < 0.05). Positive NIS staining was identified in 228 of 312 (73.1 %) patients with conventional PTC, 9 of 28 (32.1 %) patients with TCV and 12 of 30 (40.0 %) patients with DSPTC. NIS expression distinguished conventional PTC from TCV and DSPTC significantly (P < 0.01).
Conclusion
Due to their low NIS expression, TCV and DSPTC need higher cumulative doses of radioactive iodine therapy to improve their prognosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rivera M, Ghossein RA, Schoder H et al (2008) Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113:48–56
Mehta RS, Negin B, Popii V et al (2008) An aggressive radio-resistant papillary thyroid cancer. Clin Adv Hematol Oncol 6:761–767
Kloos RT (2008) Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 93:1519–1525
Dohan O, Carrasco N (2003) Advances in Na(+)/I(−) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213:59–70
Castro MR, Bergert ER, Beito TG et al (1999) Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163:495–504
Falvo L, Giacomelli L, D’Andrea V et al (2006) Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 72:438–444
Gonzalez–Gonzalez R, Bologna-Molina R, Carreon-Burciaga RG et al (2011) Papillary thyroid carcinoma: differential diagnosis and prognostic values of its different variants: review of the literature. ISRN Oncol 2011:915925
Chow SM, Chan JK, Law SC et al (2003) Diffuse sclerosing variant of papillary thyroid carcinoma–clinical features and outcome. Eur J Surg Oncol 29:446–449
Silver CE, Owen RP, Rodrigo JP et al (2011) Aggressive variants of papillary thyroid carcinoma. Head Neck 33:1052–1059
Hawk WA, Hazard JB (1976) The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 43:207–215
Stern Y, Medelia O, Feinmesser M et al (1996) Nuclear DNA content of the tall cell variant of papillary carcinoma of the thyroid gland. Ann Otol Rhinol Laryngol 105:713–715
Kumarasinghe MP, Kollure SK (1996) An aggressive variant of papillary carcinoma of thyroid: the tall cell type. Ceylon Med J 41:25–27
Lam AK, Lo CY (2006) Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13:176–181
Mizukami Y, Nonomura A, Michigishi T et al (1990) Diffuse sclerosing variant of papillary carcinoma of the thyroid. Report of three cases. Acta Pathol Jpn 40:676–682
van den Brekel MW, Hekkenberg RJ, Asa SL et al (1997) Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope 107:254–259
Martins-Filho R, Ward LS, Amorim BJ et al (2010) Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: knowing when to stop. Arq Bras Endocrinol Metabol 54:807–812
Albareda M, Puig-Domingo M, Wengrowicz S et al (1998) Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 8:385–391
Morari EC, Marcello MA, Guilhen AC et al (2011) Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol (Oxf) 75:247–254
Castro MR, Bergert ER, Goellner JR et al (2001) Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86:5627–5632
Ostrowski ML, Merino MJ (1996) Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964–974
Ozaki O, Ito K, Mimura T et al (1996) Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20:695–698
Acknowledgments
We thank Dr. Baocun Sun for providing material and Dr. Xiubao Ren for his technical assistance. This work was supported in part by grant from the National Natural Science Foundation of China (31200574) and Science and Technology Planning Project of Tianjin (12JCQNJC07700).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
S. Wei and M. Gao contributed equally to this work.
About this article
Cite this article
Wei, S., Gao, M., Zhao, C. et al. Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma. Int J Clin Oncol 19, 800–804 (2014). https://doi.org/10.1007/s10147-013-0620-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-013-0620-z